New York State Teachers Retirement System Sells 26,141 Shares of Pfizer Inc. $PFE

New York State Teachers Retirement System decreased its holdings in Pfizer Inc. (NYSE:PFE) by 0.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,637,857 shares of the biopharmaceutical company’s stock after selling 26,141 shares during the quarter. New York State Teachers Retirement System’s holdings in Pfizer were worth $130,231,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Sierra Summit Advisors LLC acquired a new position in Pfizer during the 1st quarter worth about $222,000. Private Advisor Group LLC raised its position in shares of Pfizer by 0.9% during the first quarter. Private Advisor Group LLC now owns 789,052 shares of the biopharmaceutical company’s stock worth $22,157,000 after acquiring an additional 7,340 shares during the last quarter. Optas LLC raised its position in shares of Pfizer by 42.0% during the first quarter. Optas LLC now owns 13,842 shares of the biopharmaceutical company’s stock worth $389,000 after acquiring an additional 4,095 shares during the last quarter. Y Intercept Hong Kong Ltd lifted its stake in shares of Pfizer by 146.2% in the first quarter. Y Intercept Hong Kong Ltd now owns 299,137 shares of the biopharmaceutical company’s stock worth $8,400,000 after acquiring an additional 177,627 shares during the period. Finally, Elemental Capital Partners LLC bought a new stake in Pfizer in the first quarter valued at approximately $570,000. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

PFE stock opened at $24.29 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The firm’s fifty day moving average is $25.68 and its 200 day moving average is $26.24. The firm has a market cap of $138.45 billion, a P/E ratio of 18.54 and a beta of 0.35. Pfizer Inc. has a 52 week low of $23.11 and a 52 week high of $28.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same quarter last year, the firm earned $0.92 EPS. The company’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on PFE shares. Morgan Stanley raised their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a research note on Tuesday, June 23rd. HSBC upped their target price on Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price target for the company in a report on Tuesday, June 9th. Finally, Guggenheim lifted their price objective on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average target price of $28.82.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.